Review Article

Epidemiology of Enterocytozoon bieneusi Infection in Humans

Olga Matos, 1 Maria Luisa Lobo, 1 and Lihua Xiao 2

1 Grupo de Protozoários Oportunistas/VIH e Outros Protozoários, Unidade de Parasitologia Médica, CMDT, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, 1349-008 Lisboa, Portugal
2 Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

Correspondence should be addressed to Olga Matos, omatos@ihmt.unl.pt and Lihua Xiao, lax0@cdc.gov

Received 28 February 2012; Accepted 20 May 2012

A review was conducted to examine published works that focus on the complex epidemiology of Enterocytozoon bieneusi infection in humans. Studies on the prevalence of these emerging microsporidian pathogens in humans, in developed and developing countries, the different clinical spectra of E. bieneusi intestinal infection in children, in different settings, and the risk factors associated with E. bieneusi infection have been reviewed. This paper also analyses the impact of the recent application of PCR-based molecular methods for species-specific identification and genotype differentiation has had in increasing the knowledge of the molecular epidemiology of E. bieneusi in humans. The advances in the epidemiology of E. bieneusi, in the last two decades, emphasize the importance of epidemiological control and prevention of E. bieneusi infections, from both the veterinary and human medical perspectives.

1. Introduction

Microsporidia are a group of obligate intracellular eukaryotic parasites first identified as the cause of pébrine disease of silkworms in 1857 [1]. Over the past two decades, microsporidia have risen from obscure organisms to well-recognized human pathogens. Several genera and species of microsporidia were found in humans, and diagnosis and clinical management of microsporidiosis cases have improved significantly. Despite these scientific advances, the epidemiology of human microsporidiosis is still unclear. Most of what is now known about human microsporidiosis can be attributed to experience with patients infected with human immunodeficiency virus (HIV). Since 1985 and the first recognition of Enterocytozoon bieneusi as an acquired immunodeficiency syndrome (AIDS)-associated opportunistic pathogen [2], several hundred patients with chronic diarrhea attributed to this organism have been reported. Cases of intestinal microsporidiosis due to E. bieneusi have been increasingly reported in other immunocompromised individuals such as organ transplant recipients, as well as in travelers, children, and elderly [3–12]. Hepatobiliary and pulmonary involvement has also been observed in immunocompromised persons [13–15]. Some reports in humans suggested that this species can produce asymptomatic infections in immunocompromised and immunocompetent individuals [16–20]. In addition, E. bieneusi has been commonly identified in animals, especially mammals [21–32], and water, raising public health concerns about zoonotic and waterborne transmission of microsporidia [33–35].

2. Prevalence of Enterocytozoon bieneusi in Humans

Enterocytozoon bieneusi infections in humans are mainly detected by light microscopy of stained fecal smears, electron microscopy, and PCR-based methods. Therefore, infection rates are difficult to compare because of the considerable differences in the diagnostics methods employed, the specimens analyzed, the geographical locations, the patient groups, and patients characteristics (sex, age, socioeconomic conditions, immune status, and clinical features).

In developed countries in North America, Europe, and Australia, studies involving HIV-seropositive persons with diarrhea reported rates between 2% and 78% [17, 36–45]. Lower infection rates (between 1.4% and 4.3%) were
reported in HIV-seropositive persons without diarrhea [17, 39, 43, 45]. In one study of HIV-seronegative patients with diarrhea or pneumonia, spores of *E. bieneusi* were detected in 2.5% of urine, 11.5% of fecal, and 16.2% of sputum samples examined [46]. In majority of the studies performed in developed countries *E. bieneusi* was the species detected most often, followed by *E. intestinalis*; nevertheless, these findings are not in accordance with results of a study performed recently in Czech Republic, involving immunocompetent humans [20]. In this study, *E. bieneusi* was detected four times less frequently than *E. cuniculi*, and *E. intestinalis* was identified only sporadically. Also the majority of microsporidial infections (reaching 94%) were reported for non diarrheal specimens [20]. Recently, a study was conducted in Portugal. It spans a period between 1999 and 2009, involving 856 patients (561 HIV-seropositive and 295-seronegative) and respective clinical data. The authors observed that *E. bieneusi* was more common in the HIV-seropositive group of patients (7.0%–39) than in the HIV-seronegative group (5.1%–15) [45].

In developing countries, *E. bieneusi* prevalence rates were reported between 2.5% and 51% in HIV-seropositive adult patients with diarrhea [47–60], and in 4.6% of patients without diarrhea [55]. Also in developing countries, in HIV-seronegative persons with and without diarrhea, *E. bieneusi* was detected in 5.35% to 58.1% of the fecal samples examined [19, 51, 53, 54, 61, 62]. In studies conducted in children, *E. bieneusi* prevalence ranged from 17.4% to 76.9% in HIV-seropositive children with diarrhea, and from 0.8% to 22.5% in the immunocompetent or apparently immunocompetent groups of children with or without diarrhea [18, 19, 30, 49, 63–68]. The recovery of spores of *E. bieneusi* in 0.8% of African children considered HIV seronegative, and in 5.9% of healthy orphans and 1.9% of health-care workers in Asia, indicated the presence of enteric carriage of infection in immunocompetent persons in tropical countries [49, 69]. Table 1 gives an overview of the studies conducted on the prevalence of *E. bieneusi* infection in humans, in various areas.

In industrialized nations, some studies reported *E. bieneusi* infection rates between 6.1 and 10% in travelers who suffered from self-limited diarrhea and returned from tropical destinations [6, 8]. In addition, a prevalence of 17.0% of *E. bieneusi* infection in elderly persons was observed, leading to the speculation that age-related diminishment of the immunity might predispose these persons to microsporidial infections [7].

A few prospective studies conducted in developed countries indicate that the prevalence of *E. bieneusi* in HIV-seropositive patients is progressively decreasing, probably due to the use of highly active antiretroviral therapy (HAART) [70, 71]. Similar observations are also made recently in some developing countries. In a study conducted in Brazil, comparing enteric parasitic infections in HIV/AIDS patients before and after the HAART, a statistically significant reduction in the prevalence of these infections was observed (63.9% versus 24%) [72]. Also in a 1-year longitudinal study of *E. bieneusi* infection in the same orphanage in Bangkok, Thailand, a decreasing pattern of prevalence, similar to the one observed for the incidence, was detected [19].

### 3. Patterns of *Enterocytozoon bieneusi*

**Intestinal Infection in Children**

Microsporidia are ubiquitous in nature [73], and so it should come as no surprise that they can infect humans and cause clinical disease. *E. bieneusi* was the first microsporidia species observed by transmission electron microscopy in 1982 in villus epithelial cells in small intestinal biopsies from AIDS patients with diarrhea [74]. This species is closely linked with persistent diarrhea and wasting in adults who are HIV/AIDS positive; however, the outcome of follow-up studies involving children who are also HIV/AIDS-positive and severely malnourished may be entirely different and warrants further study.

In the last decade, several studies reported the recovery of *E. bieneusi* spores from children’s stools associated to different clinical spectra (symptomatic and asymptomatic infections in HIV-seropositive and seronegative children), in different settings (Table 1).

In immunocompetent or apparently immunocompetent children, several cases of *E. bieneusi* infection have been described. In a study conducted in children considered HIV seronegative, attending two primary care centers in Niamey, Niger, *E. bieneusi* spores were recovered in 8 of 990 stool samples from these children (six males and two females, with ages ranging between 3 and 26 months). The methods used were chromotrope 2R staining and electronic microscopy for species confirmation. Seven of the *E. bieneusi* infected children were asymptomatic, and one was asymptomatic. Three of the symptomatic ones presented other intestinal coinfections with *Giardia intestinalis* (one), *Entamoeba histolytica* (another), and *G. intestinalis* and *Trichomonas intestinalis* (the third child) and complaint of diarrhea. Due to these associations, the pathogenic role of microsporidia, in these children, is difficult to ascertain. Although, for the other four symptomatic children, whose stools were positive for *E. bieneusi*, this was the only enteropathogen identified; two had diarrhea only, one had diarrhea and vomiting, and the last one complaint of vomiting, dehydration, and fever without diarrhea [49]. Also a case of dual infection with *E. bieneusi* and *Cryptosporidium* was reported in a healthy three-year-old Turkish girl (HIV seronegative) living in Germany that accompanied her family on a vacation trip to Turkey, where they resided in a rural area. Two months later the child developed profuse watery, nonbloody diarrhea, and nausea with recurrent vomiting, weight loss, and severe dehydration. The diagnosis was performed using light microscopy and electronic microscopy for microsporidia species confirmation. The girl’s diarrhea resolved without treatment after six weeks. As it happens in the above study the pathogenic role of microsporidia is difficult to ascertain in this child, due to the concomitant presence of *Cryptosporidium* in stools [10]. Another investigation was carried out to search for microsporidian spores in the stool specimens of 344 toddlers, essentially HIV seronegative, aged
Table 1: Studies on prevalence of *Enterocytozoon bieneusi* infection in humans.

| Continent | Country | Patient source                              | Major clinical presentation                      | Specimens analyzed                      | Diagnostic method                      | Prevalence (%) of *E. bieneusi* infection | Reference |
|-----------|---------|---------------------------------------------|------------------------------------------------|----------------------------------------|----------------------------------------|------------------------------------------|-----------|
| USA       | HIV+    | Chronic diarrhea                            | Intestinal biopsies                             | LM, TEM                                | 30% (20/67)                            | [16]                                     |
| USA       | HIV+    | Chronic diarrhea and other gastrointestinal complaints | Duodenal biopsies                             | TEM                                    | 33% (18/55) with chronic diarrhea; 25% (13/51) without chronic diarrhea | [83]                                     |
| USA       | HIV+    | Chronic diarrhea                            | Fecal samples, intestinal biopsies             | LM, confirmed by EM                    | 78% (14/18)                            | [36]                                     |
| USA       | HIV+    | Diarrhea, other complaints                   | Duodenal biopsies                             | PCR, confirmed by TEM                  | 44% (30/68) with diarrhea; 2.3% (1/43) without diarrhea 8.8% (137/1557) in 1993; 9.7% (193/1991) in 1994; 6.6% (155/2,346) in 1995; 2.9% (73/2,545) in 1996 | [17]                                     |
| America   | Peru    | HIV+                                        | Diarrhea                                      | Fecal samples                          | LM, confirmed by PCR                   | 3.9% (105/2,672)                         | [56]      |
| Peru      | HIV+    | Diarrhea and other gastrointestinal complaints | Fecal samples                          | LM, confirmed by PCR                   | 2.2% (56/2506)                         | [48]                                     |
| Peru      | Children apparently immunocompetent         | Diarrhea, weight loss                         | Fecal samples                          | LM, confirmed by PCR, sequence analysis | 8% (31/388)                             | [75]                                     |
| Colombia  | HIV+    | Diarrhea                                    | Fecal samples, intestinal biopsies            | LM, PCR                                | 2.9% (3/103)                           | [88]                                     |
| Brasil    | HIV+    | Chronic diarrhea                            | Fecal samples, intestinal biopsies            | LM, TEM or PCR                         | 27.5% (11/40)                          | [89]                                     |
| Cuba      | HIV+ adults; HIV− adults                    | Diarrhea, other complaints                    | Fecal samples                            | LM                                     | (0/67) in HIV+; (0/136) in HIV−          | [90]                                     |
| Portugal  | HIV+    | Diarrhea                                    | Fecal samples, gastrointestinal complaints     | LM, PCR                                | 29% (20/69)                            | [38]                                     |
| Portugal  | HIV+, HIV− adults and children              | Gastrointestinal complaints                   | Fecal samples                            | PCR                                    | 6.3% (54/856)                           | [45]                                     |
| Spain     | HIV+ children                                | 58% with diarrhea                             | Fecal samples                            | LM, confirmed by PCR                   | 1.2% (1/83); 2% (1/48) with diarrhea     | [76]                                     |
| Spain     | Returning travelers from tropical countries | Travelers’ diarrhea                           | Fecal samples                            | LM, confirmed by PCR                   | 10% (4/40)                              | [6]                                      |
| Spain     | HIV− elderly                                 | Diarrhea                                     | Fecal samples                            | LM, confirmed by PCR                   | 17.0% (8/47)                            | [7]                                      |
| Spain     | Immunocompetent                              | Diarrhea, pneumonia                           | Fecal, urine and sputum samples            | LM, PCR, hybridization                 | 11.54% (18/156) in feces; 16.22% (6/37) in sputa; 2.5% (1/40) in urine | [46]                                     |
| France    | HIV+                                           | Chronic diarrhea                             | Fecal samples and intestinal biopses         | LM, partially confirmed by EM          | 50% (9/18)                              | [41]                                     |
| France    | HIV+                                           | Diarrhea                                     | Duodenal biopsies                         | LM                                     | 1.6% (1/61)                             | [37]                                     |
| Continent | Country | Patient source | Major clinical presentation | Specimens analyzed | Diagnostic method | Prevalence (% of E. bieneusi infection) | Reference |
|-----------|---------|----------------|-----------------------------|-------------------|------------------|----------------------------------------|-----------|
| France    | HIV+    | Chronic diarrhea | Fecal samples               | LM                |                  | 24% (11/46)                             | [91]      |
|           |         |                 |                             |                   |                  | 88 HIV+ E. bieneusi infected; 12 HIV− (10 immunocompromised and 2 immunocompetent) E. bieneusi infected. |          |
| France    | HIV+; HIV− | Diarrhea       | Fecal samples               | LM, partially confirmed by EM, PCR-RFLP |                  |                                        | [92]      |
| Germany   | HIV+    | Diarrhea        | Intestinal biopsies         | PCR               |                  | 21.7% (10/46)                          | [93]      |
| Germany   | HIV+    | Chronic diarrhea | Fecal samples               | LM, PCR, sequence analysis |                  | 12 fecal samples from 8 patients        | [94]      |
| Germany   | HIV+    | Diarrhea, other complaints | Fecal samples               | LM                |                  | 36% (18/50) with diarrhea; 4.3% (2/47) without diarrhea | [43]      |
| Europe    | Germany | Human patients  | Diarrhea                    | Fecal samples     | PCR, sequence analysis | 7.7% (2/26)                          | [95]      |
|           | Germany | Returning travelers from tropical countries | Travelers' diarrhea | Fecal samples | LM, PCR | 0.7% (1/148); 4.7% (7/148) | [8]       |
| Switzerland | HIV+    | Diarrhea, other gastrointestinal complaints | Fecal samples | LM, PCR-RFLP, sequence analysis |                  | 12.7% (20/164) in 1992–94; 5.8% (9/156) in 1994–96; 0.4% (4/949) without diarrhea | [71]      |
| Holland   | HIV+    | Diarrhea        | Fecal samples               | LM, confirmed by EM |                  | 7.7% (11/143)                       | [96]      |
| UK        | HIV+    | Diarrhea        | Fecal samples, intestinal biopsies | LM, EM, confirmed by TEM |                  | 14.3% (9/63) in fecal samples; 7.9% (3/38) in biopsies | [40]      |
| UK        | HIV+    | Gastrointestinal complaints | Fecal samples | LM, PCR, qPCR, TEM |                  | 8.3% (14/168)                       | [97]      |
| Italy     | HIV+    | Chronic diarrhea | Intestinal biopsies         | LM, TEM           |                  | 4.2% (3/72)                           | [44]      |
| Czech Republic | Asymptomatic healthy people | NA | Fecal samples | PCR |                  | 6.0% (23/382)                       | [20]      |
| Russia    | HIV+, adults | Diarrhea | Fecal samples | PCR |                  | 1.3% (2/159)                       | [87]      |
| Russia    | HIV/AIDS patients | NA | Fecal samples | IFAT |                  | 13.0% (6/46)                       | [98]      |
| Tunisia   | HIV+    | Diarrhea, other gastrointestinal complaints | Fecal samples | PCR |                  | 20% (7/35) in HIV+ 5.35% (3/56) in HIV− | [62]      |
| Mali      | HIV+, and HIV− | 80% with chronic diarrhea | Fecal samples | LM, partially confirmed by TEM |                  | 32% (28/88) in HIV+; 27% (3/11) in HIV− | [51]      |
| Africa    | Mali    | HIV+ adults; HIV− children | Diarrhea | Fecal samples | LM, IFAT, PCR | 13.1% (8/61) in HIV+; 0/71 in HIV− | [47]      |
| Niger     | HIV+ (227 adults, 1 child) | NA | Fecal samples | LM, RT-PCR, sequence analysis |                  | 10.5% (24/228), all but one were adults | [76]      |
| Niger     | HIV+ adults; HIV− children | Diarrhea, other gastrointestinal complaints | Fecal samples | LM, partially confirmed by EM |                  | In adults 7% (4/60) with diarrhea; in children 1% (6/593) with diarrhea, 0.5% (2/397) without diarrhea | [49]      |
| Continent | Country       | Patient source                          | Major clinical presentation | Specimens analyzed | Diagnostic method                           | Prevalence (%) of E. bieneusi infection | Reference |
|-----------|---------------|----------------------------------------|----------------------------|--------------------|--------------------------------------------|-----------------------------------------|-----------|
| Nigeria   | HIV– children | Diarrheic and nondiarrheic children    | Fecal samples             | PCR, sequence analysis | 9.3% (4/43)                                 | [67]                                    |
| Nigeria   | HIV+ children | Diarrheic and nondiarrheic children    | Fecal samples             | LM, IFAT, PCR, sequence analysis | 2.6% (193)                                 | [68]                                    |
| Cameroon  | HIV+          | Diarrhea, other complaints             | Fecal samples             | LM, PCR-RFLP        | 6.5% (3/46) with diarrhea; 4.6% (5/108) without diarrhea | [55]                                    |
| Cameroon  | Villagers <1 to 80 years; | NA                                    | Fecal samples             | IFAT-MAb, confirmed by PCR, sequence analysis | 2.9% (22/758) in HIV–0.5% (4/758) HIV+ | [99]                                    |
| Cameroon  | HIV+ with TB; HIV– with TB; apparently immunocompetent persons | Diarrheic and asymptomatic persons | Fecal samples             | LM, IFAT-MAb             | 35.7% (10/28) in HIV+ with TB; 24.0% (6/25) in HIV– with TB; 67.5% (85/126) in immunocompetent persons | [53]                                    |
| Africa    | Gabon         | HIV+ > 16 years                         | Diarrhea, other gastrointestinal complaints | Fecal samples             | IFAT-MAb, confirmed by PCR, sequence analysis | 3.0% (25/822) | [99]                                    |
| Democratic Republic of the Congo | AIDS patients, >15 years | Diarrhea, other gastrointestinal complaints | Fecal samples             | PCR                         | 5.1% (9/175) in hospital patients | [60]                                    |
| Uganda    | Children (immune status not determined) | Diarrhea, other complaints | Fecal samples             | LM, confirmed by PCR, sequence analysis | 17.4% (310/1,779) with diarrhea; 16.8% (112/667) without diarrhea | [18]                                    |
| Uganda    | HIV+ children; HIV– children | Persistent diarrhea, dehydration | Fecal samples             | PCR                         | Overall 32.9% (80/243); 76.9% (70/91) in HIV+; 6.6% (10/152) in HIV–12.3% (30/243) in HIV+; (0/29) in HIV– 3.5% (3/86) adults; 3.4% (2/59) children with diarrhea; 20% (4/20) control children | [64]                                    |
| Ethiopia  | HIV+ and HIV– > 14 years | Diarrhea | Fecal samples             | LM, PCR               | 82% (80/243) | [82]                                    |
| Tanzania  | In patients HIV+ adults; HIV+ and HIV– children | Chronic diarrhea, other complaints | Fecal samples             | LM, TEM               | 3.5% (3/86) adults; 3.4% (2/59) children with diarrhea; 20% (4/20) control children | [77]                                    |
| Zambia    | HIV+          | Chronic diarrhea                        | Fecal samples             | LM                  | 23% (16/69)                                 | [100]                                   |
| Zimbabwe  | HIV+          | Persistent diarrhea                     | Fecal samples             | LM                  | 10% (13/129)                                 | [57]                                    |
| Zimbabwe  | HIV+          | Diarrhea                               | Formalin-fixed fecal samples | PCR                         | 46% (34/74)                                  | [101]                                   |
| Zimbabwe  | HIV+          | Diarrhea                               | Fecal samples             | LM, PCR             | 18% (10/55) by LM; 51% (28/55) by PCR        | [50]                                    |
| Zimbabwe  | HIV–          | Diarrhea, other gastrointestinal complaints | Fecal samples             | LM, confirmed by PCR | 33% (2/6)                                   | [61]                                    |
### Table 1: Continued.

| Continent | Country | Patient source | Major clinical presentation | Specimens analyzed | Diagnostic method | Prevalence (%) of *E. bieneusi* infection | Reference |
|-----------|---------|----------------|-----------------------------|--------------------|-------------------|------------------------------------------|-----------|
| Africa    | South Africa | Hospital patients, HIV+ and HIV–; school children | Diarrhea | Fecal samples | LM, PCR-RFLP, confirmed by RT-PCR | 12.9% (33/255) in hospital patients; 4.5% (3/67) of school children; 21.6% in HIV+ and 9% in HIV– with diarrhea | [54] |
|           | China    | Children | Diarrhea | Fecal samples | PCR | 22.5% (9/40) | [30] |
|           | India    | HIV+ | Diarrhea | Fecal samples | LM | 2.5% (3/120) | [55] |
|           | Thailand | HIV+ | Chronic diarrhea | Fecal samples | LM, TEM | 27.2% (18/66) | [58] |
|           | Thailand | HIV+ children; HIV– children | Diarrhea | Fecal samples | LM, confirmed by TEM | 11% (32/288) | [59] |
| Asia      | Thailand | HIV+ and HIV– children from an orphanage | Asymptomatic | Fecal samples | LM, confirmed by TEM | Overall 4.1% (12/290); 2.6% (1/39) in HIV+; 4.4% (11/251) in HIV– | [5] |
|           | Thailand | HIV+ adults | 73 HIV+, 463 HIV–; children (<11 years) and child care workers | 533 asymptomatic and 7 patients with diarrhea | Fecal samples | LM, PCR | 1.3%–6.5% overall 13.9% (75/540) | [19] |
|           | Vietnam  | HIV+ | NA | Fecal samples | LM, PCR | 5.6% (5/90) | [102] |
|           | Australia | HIV+ | Diarrhea and other gastrointestinal complaints | Duodenal biopsies | LM, RT-PCR, sequence analysis | 7.1% (3/42) | [76] |
| Oceania   | Australia | HIV+ | Diarrhea | Fecal samples | LM | 3.6% (5/139) | [103] |

LM: light microscopy, EM: electron microscopy, TEM: transmission electron microscopy, IFAT-MAb: indirect immunofluorescent assay with monoclonal antibodies, NA: not available, TB: tuberculosis, Pts: patients.

1 to 24 months, and hospitalized at a pediatric institution in Tucumán, Argentina. They were classified in two groups: I, made up of 222 children suffering from severe diarrheas, and II by 122 affected by different pathologies, except gastroenteritis. The detection of microsporidia was done by light microscopy in smears of stained stools although the determination of the species involved was not done. Coproparasitological and coprobacteriological studies were also carried out and the nutritional status of each child was determined. In group I, microsporidia were found in 7.2% (16/222) of the children, 4/68 (5.9%) belonged to eutrophic children, and 12/137 (8.8%) to undernourished children; 8/16 positives were found to be related with other enteropathogens. In group II, microsporidia were detected in 8.2% (10/122), 4/47 (8.5%) in eutrophic children, 4/54 (7.4%) in undernourished children, and without data in two cases; five out of 10 positives were related with other enteropathogens. In this study, the occurrence of intestinal microsporidia was important and did not show significant differences between toddlers with or without diarrhea, eutrophic, or undernourished children [63]. An unusual *E. bieneusi* genotype (Peru 16), transmitted from guinea pigs, was found in a 2-year-old immunocompetent child complaining of diarrhea, in Peru. This child suffered weight loss that started almost concurrently with the episode of diarrhea at the beginning of this infection episode. This finding suggests that this species may cause short-lived gastrointestinal manifestation in immunocompetent persons [75]. Also, in a study conducted in Portugal, involving 295 HIV-seronegative patients with gastrointestinal complaints, of whom 18.6% (55) were children, it was observed that microsporidians were more common in children 18.2% (10/55), than in adults 6.3% (15/240), and this difference was statistically significant (*P* = 0.012). The age of the HIV-seronegative children infected ranged from 20 months to 8 years, with a median of 3 years. The percentage of infection by *E. bieneusi* was similar in both age groups, 5.5% for children against 5.0% for the adults. In the same study, the overall percentage of HIV-seronegative patients with diarrhea (4.5%; 7), due to *E. bieneusi*, was slightly smaller than that of nondiarrheal (5.7%; 8) [45].
Studies have been conducted also in immunocompromised children, especially HIV-seropositive ones. In a prospective study conducted in Madrid, Spain, to determine the prevalence rates of microsporidiosis and other enteroparasites in 83 HIV-seropositive children treated in three hospitals of the city, *E. bieneusi* was found in 1.2% (one) of the children. Microsporidia spores were identified by staining methods and confirmed by PCR. The infected child was 10 years old and presented nonchronic diarrhea and a CD4 count of 298/mm³ [66]. In another investigation carried out in a day care treatment center and the National Hospital of Niamey, Niger, in HIV-seropositive patients, before the introduction of highly active antiretroviral therapy (HAART), one child out of a group of 24 patients, all adults, was positive for *E. bieneusi*, by real-time PCR. However, no other clinical data were provided in the study [76]. A recent study conducted in, Lisbon, Portugal, involved 126 HIV-seropositive children, in a total of 561 HIV-seropositive patients with gastrointestinal complaints of whom 18.6% (55) were children, it was observed that microsporidians were more common in children 19.0% (24), than in adults 12.4% (54). The percentage of infection by *E. bieneusi* was higher in children (10.3% 13) than in adults (6.0% 26), but this difference was not statistically significant. In the same study, the overall percentage of HIV-seropositive patients with diarrhea (8.6% 29/339), due to *E. bieneusi*, was lower than that of nondiarrheal (4.5% 10/222). Also here the difference was not statistically significant [45].

Also studies have been carrying out in institutionalized and inpatient children, independent of the HIV status. A study was undertaken in Dar es Salaam, Tanzania, to relate the protozoan infections by *Cryptosporidium* and *Cyclospora* to the protozoan infections by *Cryptosporidium*, *Microspora* sp., and *Cyclospora*. A study was undertaken in Dar es Salaam, Tanzania, and inpatient children, independent of the HIV status. Microsporidia spores were identified by transmission electron microscopy. *Enterocytozoon* was identified in specimens from 2/59 children with chronic diarrhea [77]. Another study designed in Bangkok, Thailand, investigated the prevalence and clinical features of intestinal microsporidiosis in hospitalized HIV-seropositive and seronegative children with diarrhea. Of the 95 HIV-seropositive and 87 seronegative children, 25.3% (24) and 14.9% (13), respectively, were diagnosed with intestinal microsporidiosis. Species identification of microsporidia spores by transmission electron microscopy demonstrated *E. bieneusi* in five cases. *Cryptosporidium parvum* was a common coinfective parasite. Malnutrition was commoner (one) of the children. Microsporidiosis was an important disease in both HIV-seropositive and seronegative Thai children with diarrhea [65]. In a cross-sectional, case-control study, involving children aged <60 months, with undetermined HIV status, undertaken in Kampala, Uganda, using genetic tools, a total of 17.4% of 1,779 children with diarrhea, attending a hospital, were infected with *E. bieneusi* compared with 16.8% of 667 control children (without diarrhea). There was no significant relationship between infection with *E. bieneusi* and stunting, being underweight, wasting, or acute diarrhea. The authors observed that children with a high rate of excretion of spores were more likely to have diarrhea of longer duration (P < 0.001), which they hypothesized could suggest an association with more prolonged illness. It was concluded that *E. bieneusi* was widespread among children 3–36 months of age in Uganda, and that there was no clear association of *E. bieneusi* with poor nutrition or diarrhea [18]. The same authors, in a following study involving 243 children, aged <60 months with persistent diarrhea (>14 days), admitted to the same hospital in Kampala, Uganda, using microscopy and PCR methods, screened for the presence of *E. bieneusi* and *Cryptosporidium* in the children’s stools [64]. They found that 32.9% (80) of them were excreting *E. bieneusi*, and 31.3% (76) were excreting *Cryptosporidium*. Ninety-one of the 243 children were HIV seropositive, of whom 76.9% (70) had *E. bieneusi*, versus 6.6% (10) of the 152 HIV-seronegative (odds ratio = 47.33; 95% CI = 19.88 to 115.97), while 73.6% (67) had *Cryptosporidium*, versus 5.9% (9) without HIV (odds ratio = 44.36; 95% CI = 18.39 to 110.40). Children with counts <25% CD4 cells were more likely to have either *E. bieneusi* (odds ratio = 7.42; 95% CI = 3.77 to 14.69) or *Cryptosporidium* (odds ratio = 6.45; 95% CI = 3.28 to 12.76) than those with higher CD4 percentages. However, only HIV status was independently associated with either *E. bieneusi* or *Cryptosporidium*. Among the 243 children with persistent diarrhea, 27.8% (67) were infected with both enteric pathogens, with HIV being the only independent predictor of coinfection. Finally, some 81% of HIV-seropositive children with persistent diarrhea excreted one or both organisms, compared with only 10% of children with persistent diarrhea testing negative for HIV. As in their previous study on *E. bieneusi* [18] there was no significant association between infection in this subpopulation and malnutrition even after controlling for HIV status and CD4 counts/percentages. Once more authors concluded that *E. bieneusi* as well as *Cryptosporidium* were highly prevalent in Ugandan children, especially those immunocompromised by HIV/AIDS [64]. Also a study was conducted among hospital patients and school children in Vhembe district, Limpopo Province, South Africa, for microsporidia detection using PCR-RFLP and staining methods. In the age group between 0 and 9 years, *E. bieneusi* was found in 50 children (six HIV seropositive) attending the hospital, of whom 80% (40/50) complaint of diarrhea, and in nine school children (apparently healthy) in the same age group, of whom 33% (3/9) had diarrhea [54]. In a cross-sectional study of intestinal microsporidiosis conducted, this time in Bangkok, Thailand, in children who lived in an orphanage, stool samples were collected from 290 orphans (39 HIV seropositive and 251 HIV seronegative). Stool analysis was made under light microscopy, and confirmation of species was performed using transmission electron microscopy. Of the 290 children, 4.1% (12) were positive for *E. bieneusi* [5].
Taking into consideration the results obtained in this study, the same authors conducted a 1-year-longitudinal study of *E. bieneusi* infection in the same orphanage. A total of 540 orphans and 81 child-care workers were enrolled in the study. Using microscopy and PCR methods these authors found that 13.9% (75) of the orphans had *E. bieneusi* spores in fecal samples. Only 28.6% (2/7) of the diarrheic children were infected by *E. bieneusi*. In this study *E. bieneusi* infection was significantly prevalent in children between 1 and 3 years of age with a lower incidence in the older age group, which may reflect the development of protective immunity. Nine orphans (three HIV seropositive) were reinfected (4-month intervals between two positive PCRs) in the study. Thus, the authors hypothesized that protective immunity might not be fully developed after an infection in some children since reinfection occurred [19].

Asymptomatic infections with *E. bieneusi* have been reported in both HIV-seropositive and -seronegative adults although in children the asymptomatic cases were described, so far, only in HIV-seronegative children. In a study performed in Tanzania, in four of 20 HIV-seronegative children admitted to hospital due to acute trauma or elective surgery, with no history of diarrhea in the previous 3 months, *E. bieneusi* spores were identified by staining methods and the species confirmed by transmission electron microscopy. All four asymptomatic children were underweight (*P < 0.01*). In the cross-sectional study of parasitic infection conducted in Bangkok, Thailand, in orphan children, spores of *E. bieneusi* were detected in stool specimens, by a staining method and confirmed by transmission electron microscopy, in 5.9% (13/221) of the HIV-seronegative children who had neither current illness nor history of gastrointestinal symptoms in the previous 1 month [69]. Also in Kampala, Uganda, *E. bieneusi* was detected by molecular methods in stool samples of 112 children, with undetermined HIV status, without diarrhea [18]. In the study conducted in Limpopo Province, South Africa, *E. bieneusi* asymptomatic infections were detected in 20% (10/50) of the children aged 0 to 9 years, observed in the hospital, and in 67% (6/9) of the school children enrolled in the study, by PCR methodology [54]. In another study, in Cameroon, *E. bieneusi* was, once more, detected in stools samples from healthy persons without symptoms, including teenagers (12–19 years old) and children in the age group between 0 and 11 years. The percentage of infection increased with age; however, children had the highest parasite loads [55].

The pathogenicity of microsporidia is still not clearly defined, and the mechanism by which they induce diarrhea has not been determined. Some authors found that even though HIV-positive patients infected by *E. bieneusi* had more diarrhea than those noninfected, they in fact had less inflammation than the noninfected HIV-positive individuals, demonstrated by a lactoferrin test, even though some genotypes of *E. bieneusi* can cause chronic diarrhea [48, 54].

*Enterocytozoon bieneusi* can be an important cause of persistent diarrhea, intestinal malabsorption, and wasting in HIV-positive adults. Mucosal damage associated with microsporidiosis is more extensive than that related to other opportunistic intestinal infections and leads to substantial malabsorption of vitamins, micronutrients, carbohydrates, and fats [71, 78, 79]. Although microsporidiosis is common in children ≤5 years of age, particularly those who live in developing countries or who are HIV-seropositive, the effects of infection on nutritional health of these vulnerable populations were not well documented until recently [18, 64, 65, 80]. In a study conducted in Uganda, in children ≤60 months of age with persistent diarrhea *E. bieneusi* was associated with lower rates of weight gain. This relationship remained after controlling for HIV and concurrent coccidiosis. Children with microsporidiosis were predicted to weigh 1.3 kg less than children without microsporidiosis at 5 years of age [81].

Diarrhea and malabsorption seem to be the most common clinical problems associated with microsporidian infections, namely, *E. bieneusi*, reported in the literature [14, 46, 82]. However in some studies there were no statistically significant associations between the presence of microsporidia, namely *E. bieneusi*, in faecal specimens and patients with diarrhea [45, 55, 83–85]. Several studies suggest that *E. bieneusi* infection can remain asymptomatic suggesting that some persons may be asymptomatic carriers of these microorganisms [19, 49, 69, 77].

4. Risk Factors Associated with *Enterocytozoon bieneusi* Infection

Since the identification of *E. bieneusi* as a pathogen in humans, it has been shown to be a major cause of chronic diarrhea in HIV-seropositive persons. Some studies have tried to identify risk factors for *E. bieneusi* infection in humans (Table 2). Immunodeficiency, especially that associated with HIV/AIDS, low CD4+ T cells count (≤50 cells per microliter blood), and younger age are all considered risk factor for intestinal microsporidiosis due to *E. bieneusi* [18, 19, 45, 64, 86, 87]. In Ethiopia, in a study conducted in 214 HIV-seropositive and 29 HIV-seronegative patients with diarrhea, microsporidal parasites (*E. bieneusi* and *E. intestinalis*) were detected only in HIV-seropositive patients (39). Among the patients studied 92.3% had diarrhea for over four weeks, and 94.9% had weight loss of more than 10% [82]. Also in a recent study performed in Russia, involving 139 HIV-seropositive patients, a statistically significant association was observed between the microsporidia positive patients and weight loss of >10% of the baseline (63%; 19/30) [87]. In a 10-year study, performed in Portugal, involved 856 (675 adults and 181 children) HIV-seropositive and -seronegative patients with gastrointestinal complaints, an immunosuppressive condition and youth (children) were the risk factors observed for microsporidian infection [45].

Other risk factors associated with intestinal microsporidiosis, in general, or particularly to *E. bieneusi* infection have been reported. A US study of HIV-seropositive patients with diarrhea showed significant association of intestinal microsporidiosis with contact with horses, having been stung by a bee, hornet, or a wasp, and having used injection drugs. The use of hot tub or spa and occupational contact with water also reached statistical significance in this study [86].
E. bieneusi has been able to cause clinical disease in immunocompromised and immunocompetent persons with different patterns, and the risk factors associated with these pathologies are partially known as a result of improvement in genetic typing and molecular epidemiology.

5. Molecular Epidemiology of Enterocytozoon bieneusi in Humans

The combination of epidemiologic studies with genotyping techniques has contributed to a better understanding of the characteristics of microsporida that infect humans and of its reservoirs and transmission patterns. Before the introduction of the molecular tools, the characterization of this important group of parasites relied exclusively on electron microscopic observations of the morphological differences in spores and/or endogenous developmental stages and host occurrence. The recent application of PCR-based molecular methods for species-specific identification and genotype differentiation of microsporida has increased research interests in this group of microorganisms. The enhanced diagnostic capacity obtained with the molecular methods has improved the identification of human cases of microsporidiosis due to E. bieneusi, not only in developed countries [6, 7, 17, 20, 30, 38, 45, 62, 66, 81, 87, 92, 108, 112, 115], but also, and especially, in developing countries where E. bieneusi may be a public health problem due to the magnitude of the HIV pandemic and poor sanitary conditions [18, 19, 30, 47, 48, 50–52, 54–56, 62, 64, 68, 88, 89, 99, 102].

Enterocytozoon bieneusi is a complex species with multiple genotypes and diverse hosts range and pathogenicity. Since different strains cannot be discriminated morphologically, typing of this species relies on molecular methods [22]. PCR analysis of the internal transcribed spacer (ITS) of the rRNA gene, a hypervariable sequence with about 243 bp long, followed by sequencing of the PCR products and comparison of obtained ITS sequences with those in the databases, is the standard method for genotyping E. bieneusi isolates from humans and animals. For several years these were the only genetic markers available [22, 56, 104, 133–136]. A few researchers genotyped E. bieneusi based on the analysis of the ITS by PCR-restriction fragment length polymorphism (RFLP) [92, 109]. And recently, two groups of researchers reported the analysis of the GenBank E. bieneusi ITS sequence collection, using statistical methods, with the aim to obtain information about diversity, transmission, and evolution of this species [135, 136]. These studies have identified the presence of host-adapted E. bieneusi genotypes in a variety of domestic animals and wild mammals, as well as a large group of E. bieneusi genotypes that do not appear to have host specificity [24, 25, 135, 136]. These latter genotypes, considered zoonotic, are responsible for most human infections. E. bieneusi genotypes in humans have been shown to differ from each other in virulence and geographic distribution [48, 136]. Other authors, taking advantage of the current genome sequence surveys of E. bieneusi, identified four polymorphic microsatellite and

| Table 2: Risk factors associated with Enterocytozoon bieneusi infection. |
|-----------------------------|-----------------------------|
| Risk factor | Reference |
| HIV/AIDS | [45, 64, 82, 86, 104] |
| Low CD4+ T cells count | [86] |
| Younger age | [18, 45, 64] |
| Person-to-person transmission | [5, 19, 50] |
| Injection drugs | [86] |
| Living in rural areas: contact with animals | [50] |
| - Contact with cow dung | [50] |
| - Contact with horses | [84] |
| - Contacts with duck or chicken droppings | [48] |
| - Having been stung by bees, hornets, or wasps | [84] |
| Food: watermelon consumption | [48] |
| Water | |
| - Consumption of nonpiped water | [50] |
| - Hot tub, spa, and occupational contact with water | [86] |
| - Contact with ground, surface, ditch, and crop irrigation water sources | [33, 105, 107] |
| Poor sanitation | |
| - Lack of flush toilet | [48] |
| - Lack of garbage collection | [48] |
| - Lack of running water | [48] |

Also person-to-person transmission has been suggested in an orphanage, where a multivariate analysis showed that orphans who were 12–23 months old, girls, and living in one particular house were independently associated with E. bieneusi infection. All infected children presented the same E. bieneusi genotype in stools [5, 19]. Another study in Zimbabwe showed association of E. bieneusi infection in HIV-seropositive patients with living in rural areas, consumption of nonpiped water, contact with cow dung, and contact with a person with diarrhea [50]. These authors postulated the reasons for the unclear association between injection drug use and enteric microsporidiosis stating that injection drug users were as likely or more likely to contact potential infectious sources, such as contaminated water. Contact with water is an important risk factor consistently associated with E. bieneusi infection in epidemiologic studies, and E. bieneusi spores have been detected in ground, surface, ditch, and crop irrigation water sources [33, 105–107, 132]. However, no significant seasonal variation has been detected in the prevalence of intestinal microsporidiosis in HIV-seropositive patients [70]. In a study of HIV/AIDS patients performed in Peru, risk factors for E. bieneusi infection differed by genotype. Infection with genotype Peru-1, one of the more common genotypes found, was associated with contact with duck or chicken droppings and lack of running water, flush toilet, or garbage collection. In contrast, genotypes Peru-2 to Peru-11 were associated with watermelon consumption [48].
minisatellite markers. Together with the ITS, they became part of a multilocus sequence typing (MLST) technique developed for genotyping *E. bieneusi* that could be useful in epidemiologic investigations of *E. bieneusi* transmission, especially those concerning the public health significance of parasites of animal origin [137]. The observations, obtained with the study of the ITS locus, were also corroborated with the phylogenetic analysis of the polymorphic microsatellite and minisatellite markers, identified by Feng and collaborators in the *E. bieneusi* genome. These authors observed the formation of two large groups of *E. bieneusi*: zoonotic genotypes and host-adapted genotypes [137].

Actually, more than 90 different genotypes of *E. bieneusi*, identified by ITS sequence, have been described in humans and animals, and some genotypes have multiple names that have been reviewed in Satin and Fayer, 2011 [138] who tabulated all the existing synonyms for the first time and proposed a standardized nomenclature for *E. bieneusi* genotypes based on the ITS sequences. About 34 of these genotypes have been found only in humans [5, 18, 24, 48, 75, 76, 92, 94, 99, 109, 112, 114, 115] (Table 3), and 11 genotypes have been reported both in humans and animals [18, 21, 24–29, 48, 55, 56, 75, 76, 92, 95, 99, 102, 109, 111–114, 116, 118–127, 129, 139] (Table 4). All these observations were made in populations from different geographic regions, involving all continents.

In studies conducted in France involving HIV seropositive and seronegative patients infected with *E. bieneusi*, Liguory and collaborators found five genotypes (Types I to V) [109, 112]. Type I, synonym of genotype B, was the most prevalent genotype (75%). It was followed by Type II, designated as genotype C (10%). Genotypes B (Type I) and C (Type II) were also found in other populations [94, 95, 99, 111, 112, 115]. Genotype B (Type I) even showed predisposition toward HIV/AIDS patients [112] and was the only genotype found in a study performed in HIV-seropositive patients in Australia [115]. Type IV, also named genotype K/Peru2/PtEbIII/BE5/BE5-var/CMITS1, was rare (only in one human isolate) [92]. In contrast, Type IV (genotype K) was the only genotype found in a population in Cameroon [55]. Moreover, this genotype was also found in humans in other regions [18, 48, 56, 75, 76, 99, 111, 112] and in various animals [25–27, 122–125]. Type V was found only in one HIV-seropositive person.

In Lima, Peru, in a population of 2,672 HIV/AIDS patients, 11 genotypes were identified (Peru-1 to Peru-11). The most prevalent genotypes were Peru-1 (39%), synonym of genotype A, Peru-2 (19%), synonym of Type IV, and Peru-9 (10%), also named genotype D; the remaining eight genotypes were found in the population at much lower frequencies (1–9%) [48, 56, 75]. Some of these genotypes were also found in animals, including genotype A (Peru-1), Type IV (Peru-2), Peru-4, also named genotype EbPC/E/WL15/WL17, to Peru-6, also named PtEb/PtEbVII, Peru-7, D (Peru-9), Peru-10 and Peru-11, also named Peru-12 [21, 24–28, 32, 55, 75, 95, 114, 116, 117, 121–126]. Three genotypes (A/Peru-1, Peru-7, and Peru-11), found until recently only in humans, were also identified in animals [32, 117]. Both genotypes D and Type IV (reported as genotype K) were the most prevalent among patient groups from Malawi and The Netherlands [112]. Genotype D that was commonly detected in HIV-seropositive patients was also found in HIV-seronegative individuals, confirming its widespread nature [56, 99, 101, 102, 111, 113]. In a study conducted in renal transplant recipients in Spain, genotype D was the only *E. bieneusi* genotype found [108].

Also in Peru, in a prospective pediatric-cohort study of enteric parasites, *E. bieneusi* infection was identified in 31 of 388 (8%) children [75]. Thirty of these children had infections with genotypes Peru-1 (synonym of A) through Peru-13 and Peru-17, and one child was infected with genotype Peru-16. Fecal samples of all animals in the household of child infected with Peru-16 were also analyzed including guinea pigs, chickens, dogs, and cats. Peru-16 was identified in seven of the eight guinea pigs studied, and all the other animals were negative for microsporidia. This genotype was genetically very different from other known *E. bieneusi* genotypes in humans and was placed, in an independent clade, outside the cluster of genotypes considered to have broad host specificity in a phylogenetic analysis of the ITS sequences. The finding of genotype Peru-16 in guinea pigs from unrelated households, and the close contacts between the study child and infected guinea pigs, all strongly suggested that the child probably acquired the infection from the guinea pigs in the household [75]. This finding indicated that even some *E. bieneusi* genotypes that are apparently unique in some animals have zoonotic potential [119]. One of the genotypes, Peru-14, also named genotype WL15/WL16, was also found in animals [24].

Genotype UG2145, identified for the first time in Uganda, was the only *E. bieneusi* detected in a population of 1,779 children with diarrhea [18].

Some genotypes like genotypes B and C are considered host specific because they were exclusively found in humans. However, it must be kept in mind that they differ in very few base pairs from other sequences commonly found in other hosts. For instance, genotype type IV differs from B in 3 bp, and from A in just 1 bp. In contrast, some other genotypes have a zoonotic potential (such as genotypes D and Type IV, and more recently genotype A) because they have been seen in various animals [18, 24–27, 29, 48, 75, 76, 95, 111, 112, 116, 118, 119, 122–124, 126, 127, 129, 139].

Breton and collaborators revealed for the first time the presence of genotypes A and B in Africa [99]. These genotypes were also reported from HIV-seropositive and HIV-seronegative populations in Europe [92, 94, 109, 111, 112, 121], Peru [56, 75], Thailand [5, 114], and Niger [76]. In Breton and collaborators study, genotype D was found in one HIV-seropositive patient in Gabon, and it was identified for the first time in isolates from three HIV-seronegative individuals in Cameroon [99]. It is considered a genotype with a broad host and geographic range, having been found in several countries in Europe [26, 111, 112, 127], USA [24, 119], Peru [48, 56, 75], Malawi [112], Thailand [5, 102], Vietnam [76], and Korea [124, 129]. Three new genotypes CAF1, CAF2, and CAF3 that are close relatives of genotypes E, Type IV, and D, respectively, were found for the first time in the HIV-seropositive patients from Gabon, with
| Continent | Country | Year | Patient source | Genotype (synonyms)/no. of isolates | Reference |
|-----------|---------|------|----------------|------------------------------------|-----------|
| Peru      | 2003    | HIV+ |                | A (Peru1)/82, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/41, Peru3/2, EbpC (E, WL13, Peru4, WL17)/4, WL11 (Peru5)/8, Peru6 (PtEb I, PtEb VII)/1, Peru7/18, Peru8/10, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/24, Peru10/6, Peru11 (Peru12)/16. | [56] |
| America   | Peru    | 2000–2002 | HIV+ | A (Peru1)/35, Peru3/1, Peru7/8, Peru8/4, Peru11 (Peru12)/6, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/9, EbpC (E, WL13, Peru4, WL17)/1, Peru10/3, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/18, WL11 (Peru5)/3, Peru6 (PtEb I, PtEb VII)/1. | [48] |
| Peru      | 2007    | Children apparently immunocompetent |                | A (Peru1), Type IV (K, Peru2), Peru3, EbpC (Peru4), WL11 (Peru5), Peru6 (PtEb I, PtEb VII), Peru7, Peru8, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc), Peru10, Peru11 (Peru12), Peru13, WL15 (Peru14), Peru15, Peru16, Peru17 | [75] |
| Portugal  | 1999–2009 | HIV+, HIV−; Adults and children |                | Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/18, Peru6 (PtEb I, PtEb VII)/14, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/6, A (Type II)/3, PtEb II/3. | [45] |
| Spain     | 2009    | HIV−; renal transplant recipients | HIV−; immuno-compromised HIV− | D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/2 | [108] |
| France    | 1998    | HIV+ |                | B (Type I)/51 HIV+, C (Type II)/6 HIV+, 2 HIV−, Type III/3 HIV+, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/3 HIV+ | [109] |
| France    | 2001    | HIV+; HIV− |                | B (Type I)/66 HIV+, C (Type II)/9 HIV+, 8 immunocompromised HIV−, and 1 immunocompetent , Type III/3 HIV+, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/9 HIV+, 2 immunocompromised HIV−, 1 immunocompetent, Type V/1 HIV+ | [92] |
| Germany   | 1993    | HIV+ |                | A (Peru1)/3, B (Type I)/3, C (Type II)/2 | [94] |
| Germany   | 2001    | Human patients |                | C (Type II)/1, Q/1 | [95] |
| Switzerland | 2000  | Human patients |                | Q | [110] |
| UK        | 1992–1995; 2002 | HIV+ |                | B (Type I)/11, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/1, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/1 | [111] |
| The Netherlands | 1996–2007 | HIV− |                | A (Peru1)/1, B (Type I)/4, C (Type II)/5, S7/1, S8/1, S9/1, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/2, Type IV (K)/5, | [112] |
| Czech Republic | 2008–2009 | HIV− |                | EbpA/10, C3/4, PigEBITS5/3, BFRmr2/2, BEB4/2, CZ1/1, CZ2/1 | [20] |
| Russia    | 2007    | HIV+ patients |                | D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/2 | [87] |
| Niger     | 2007    | HIV+ (227 adults, 1 child) |                | A (Peru1)/10, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/1, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/1, CAF1 (PebE)/2, NIA1/3 | [76] |
| Nigeria   | 2011    | Children with and without diarrhea |                | D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/2, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/1, new genotype (similar to genotype K (with two nucleotide substitutions))/1 | [67] |
| Nigeria   | 2012    | HIV+ |                | B/1, new genotype (similar to P, Type IV, UG2145; Peru3, PtEb IV, PtEb VI)/2 | [68] |
| Cameroon  | 2006    | HIV+ Villagers <1 to 80 years; 0.5% (4/758) HIV+ |                | Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/4 | [55] |
| Cameroon  | 2007    | HIV+ Villagers <1 to 80 years; 0.5% (4/758) HIV+ |                | A (Peru1)/8, B (Type I)/3, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/3, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/1, CAF4/5 | [99] |
| Gabon     | 2007    | HIV+ >16 years |                | A (Peru1)/1, D (WL8, Peru9, PigEBITS9, PtEb VI, CEBc)/1, TypeIV (K)/4, CAF1 (PebE)/3, CAF2/1, CAF3/1, CAF4/4 | [99] |
| Uganda    | 2002    | Children (immune status not determined) |                | Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/6, UG2145/1 | [18] |
| Continent | Country | Year       | Patient source                                      | Genotype (synonyms)/no. of isolates                                      | Reference |
|-----------|---------|------------|----------------------------------------------------|-------------------------------------------------------------------------|-----------|
| Africa    | Malawi  | 2003-2004  |                                                     | Peru8/1, UG2145/1, S1/2, S2/11, S3/2, S4/1, S5/4, S6/2, D (WL8, Peru9, PigEBITS9, PtEb VI, CEbc)/4, Type IV (K, Peru2, BEB5, BEB5-var, CMITS1, PtEb III)/8 | [112]     |
|           |         |            |                                                     | I (BEB2, CEbE)/3, J (BEB1, CEbB, PtEb X)/3, CHN1/5, CHN2/2, CHN3/4, CHN4/3 | [30]      |
|           |         |            |                                                     | A (Peru1)/10.                                                          | [5]       |
| Asia      | Thailand| 2005       | Asymptomatic adults (5) and children (2)            | A (Peru1)/7                                                            | [114]     |
|           | Thailand| 2006       | HIV+ (33 adults)                                     | D (WL8, Peru9, PigEBITS9, PtEb VI, CEbc)/12, Ebp C (E, WL13, Peru4, WL17)/5, O/1, R/1, S/4, T/1, U/1, V/1, W/1, Peru 11 (Peru12)/2, PigEBITS7/4. | [113]     |
|           | Thailand| 2005       | HIV+ and HIV− children from an orphanage            | D (WL8, Peru9, PigEBITS9, PtEb VI, CEbc)/5                             | [102]     |
|           | Thailand| 2003-2004  | HIV+ and HIV− children from an orphanage            | A (Peru1)/75                                                           | [19]      |
| Vietnam   |         | 2007       | HIV+                                               | D (WL8, Peru9, PigEBITS9, PtEb VI, CEbc)/1, Ebp C (E, WL13, Peru4, WL17)/1, HAN1/1 | [76]      |
| Oceania   | Australia| 2005–2007  | HIV+ (men) with diarrhea; CD4+ T-cell counts < 100 cells mm⁻³ | B (Type I)/29                                                          | [115]     |

10 out of 15 isolates. CAF1 was also found in pigs in Korea [120]. Another new genotype, CAF4, a highly divergent genotype reported from humans, was equally present in HIV-seropositive patients in Gabon and HIV-seronegative individuals in Cameroon. Its high frequency (25%) in both countries may indicate that this genotype is common in Central Africa [99].

Ten Hove and collaborators found nine new genotypes: six (S1-S6) were from Malawi, and three (S7-S9) were from The Netherlands [112]. Genotype S7 showed no linkage to any of the described genotypes and seems to be more related to the genotypes isolated from cattle. The patient (HIV infection was considered unlikely) infected with this *E. bieneusi* genotype was a middle-age man presenting severe diarrhea and rectal bleeding. Two other new unnamed genotypes were detected in this study, AF502396 and AY371283, actually named as UE2145 and Peru-8, respectively.

In a study conducted in Changchun City, China, involving 40 fecal samples from diarrheal children and 180 fecal samples from animals (61 from pigs, 26 from dogs and 93 from cows), all collected in the same area around the city, Zhang and collaborators found two previously reported genotypes (genotypes I and J), and 10 new genotypes (CHN1-10) [30]. Genotypes I (also named BEB2/CEbE) and J (also named BEB1/CEbB, PtEb X), originally detected in cattle [25], were identified in both cow and human samples in this study. Both genotypes coinfected with other genotypes in all positive samples. Of the novel genotypes, CHN1, which was detected in five children, nine cows, and four pigs, was the most common genotype found in this study. Genotype CHN2 was found only in human samples. Genotypes CHN3 and CHN4 were also found in both human and cow samples, and genotypes CHN5-10 were only detected in animals. The ITS sequences of the 10 new genotypes were highly homologous to those of genotypes I, J, Type IV, and G published earlier [25, 75, 101, 109, 129]. Genotypes CHN1, CHN2, and CHN3 differed from J by one to four positions, while genotype CHN4 is 2 bp shorter than type IV. Due to the high level of similarity of the sequences, no obvious clusters related to host preference were observed [30].

In a study that investigated the occurrence and prevalences of the microsporidial species *Enterocytozoon bieneusi* and *Encephalitozoon* spp. in 382 immunocompetent humans in the Czech Republic the sequence analyses of *E. bieneusi*-positive samples revealed seven different genotypes [20]. For the first time, after so many studies performed in humans, in different geographic areas, genotypes that were previously reported only from cattle (BEB4 and EbpA) and pigs (PigEBITS5, EbpA, and BFRmr2) were identified in humans, and three new genotypes were detected (*E. bieneusi* CZ1 to CZ3). The most prevalent *E. bieneusi* genotypes were EbpA (in 10 individuals), CZ3 (in 4 individuals), and PigEBITS5 (in three individuals), followed by BFRmr2 and BEB4 (each in two individuals). The CZ1 and CZ2 genotypes were identified only in single individuals. In the same study *E. cuniculi* genotype II was also found in humans. These data suggest that isolates of this group are able to switch hosts from animals to humans and should be regarded as isolates with high zoonotic potential. The high prevalences of microsporidia infection surprisingly found in
| Genotype designation | Hosts                                                                 | Reference(s)          |
|----------------------|----------------------------------------------------------------------|-----------------------|
| A                    | Humans, baboons and birds.                                           | [19, 48, 56, 75, 76, 94, 99, 112–114, 116, 117] |
| D (PigITS9, WL8, Per9, PtEbVI, CEBc) | Humans, macaque, baboons, pigs, cattle, horse, dogs, fox, raccoon, beaver, muskrat, and falcons | [24, 26, 29, 56, 75, 76, 87, 89, 99, 102, 108, 111, 112, 118, 119] |
| CAF1 (PebE)          | Humans and pigs.                                                     | [76, 99, 120]         |
| EbpC (E, WL13, WL17, Peru4) | Humans, pigs, beaver, otter, muskrat, raccoon, and fox.             | [2, 21, 24, 28, 48, 56, 75, 76, 110, 113, 114, 116, 121] |
| Peru16               | Humans and guinea pigs                                              | [75]                  |
| Peru10               | Humans and cats                                                     | [48, 56, 75, 122, 18, 25–27, 48, 55, 56, 75, 76, 92, 95, 99, 109, 111, 112, 122–124] |
| Type IV (K, Peru2, PtEbIII, BEB5, BEB5-var) | Humans, cattle, cats, and dogs.                                      | [20, 28, 95, 116, 119, 121, 127, 128] |
| WL11 (Peru5)         | Humans, dogs, fox, and cats                                          | [24, 48, 56, 75, 122, 123] |
| O                    | Humans and pigs.                                                     | [28, 95, 113, 114]    |
| PigEBITS7            | Humans and pigs.                                                     | [113, 119]            |
| Peru6 (PtEbI, PtEbVII) | Humans, cattle, dogs, and birds                                      | [26, 45, 48, 56, 75, 125, 126] |
| WL15 (WL16, Peru14)  | Humans, beaver, fox, muskrat, and raccoon                           | [24, 56, 75]          |
| EbpA (F)             | Humans, cattle, pig, and birds                                       | [20, 28, 95, 116, 119, 121, 127, 128] |
| I (BEB2, CebE)       | Humans and cattle.                                                   | [25, 30, 95, 124, 126, 128–130] |
| J (BEB1, CebB, PtEb X) | Humans, cattle, and birds                                            | [25, 26, 30, 95, 124, 126, 128–131] |
| Peru7                | Humans and baboons                                                  | [48, 56, 75, 117]     |
| Peru11 (Peru12)      | Humans and baboons                                                  | [48, 56, 75, 113, 117] |
| BEB4                 | Humans and cattle.                                                   | [20, 25, 29, 126, 130] |
| PigITS5 (PebA)       | Humans and pigs.                                                     | [20, 116, 119, 120]   |
| BFRmr2               | Humans and pigs.                                                     | [20, 28]              |
| CHN1                 | Humans, cattle and pigs.                                             | [30]                  |
| CHN3                 |Humans and cattle                                                     | [30]                  |
| CHN4                 | Humans and cattle                                                    | [30]                  |
| PtEb II              | Humans and birds                                                    | [45, 125]             |

Different populations of immunocompetent humans in this study raise the question of whether these findings represent true infection resulting in shedding of parasites or ingested parasites that just passed through the gastrointestinal tract without establishing an infection. However, the chance of detecting the temporary passage of spores is quite low in the number of individuals sampled analyzed in this study [20]. Several studies indicate that the distribution of genotypes of E. bieneusi can vary by geographical locations [95], and it has been recently proposed that predominant genotypes...
in different geographical sites could be related to distinct sources of transmission [5]. In a comparative study of the molecular epidemiology of microsporidiosis among HIV-seropositive patients in two separate geographical areas, Niamey, Niger and Hanoi, Vietnam, interesting results were obtained. In Hanoi, two zoonotic genotypes D and E were identified [76]. Both genotypes have been previously recovered in both humans and animals [21, 24, 26, 56]. These genotypes were also predominant in a study conducted in Thailand in HIV-seropositive patients [113]. Thus, there is a potential zoonotic transmission of *E. bieneusi* in Thailand and Vietnam. Zoonotic transmission can be from direct exposure to animals or by contamination of surface water by discharged domestic wastewater or animals. On the contrary, the Niamey data highlighted a higher frequency of genotypes known to be human specific (genotype A), similar to results obtained in children from an orphanage in Thailand [5]. These results suggest that transmission of microsporidiosis due to some *E. bieneusi* genotypes could occur through person-to-person contact. This mode of transmission could be facilitated by chronic carriage of *E. bieneusi*, as described in previous studies [49, 140].

All these findings suggest different transmission modes of *E. bieneusi* in diverse geographic regions and in special groups in the same region. However, further studies with larger number of *E. bieneusi* samples are needed to confirm these findings.

### 6. Conclusion

Despite recent advances in the understanding and diagnosis of *E. bieneusi*, emerging microsporidian pathogens, more research is necessary to elucidate their complex epidemiology. In fact, studies that reflect true human infecting *E. bieneusi* prevalence are still insufficient. A few prospective studies conducted in developed countries indicate that the prevalence of *E. bieneusi* in HIV-seropositive patients is progressively decreasing, probably due to the use of HAART. Similar observations have also been made recently in some developing countries. The recovery of spores of *E. bieneusi* in fecal samples of children considered HIV-seronegative, and in healthy ones, indicated the presence of enteric carriage of infection in immunocompetent persons in tropical countries, but also in other regions of the globe. Also, the finding of asymptomatic chronic carriers of *E. bieneusi* emphasizes their importance in the transmission cycle, warning for the potential risk of reactivation of latent infection in cases of immunosuppression causing life-threatening disease in these individuals.

The pathogenicity of microsporidia is still not clearly defined, and the mechanism by which they induce diarrhea has not been determined. Even though some genotypes of *E. bieneusi* can cause chronic diarrhea and wasting syndrome in AIDS patients once the CD4+ T-lymphocyte count drops below 100 cells/mm³.

The recent application of PCR-based molecular methods to *E. bieneusi* identification and characterization has led to more reliable results compared with prevalence rates determined by light microscopy of stained biological smears, to better study the risk factors associated with these pathologies, to study the distribution of genotypes of *E. bieneusi* by geographical location, to improve source tracking, and to calculate the host range and pathogenic potential of an isolate. All typing studies performed until now were based on the analysis of the ITS sequences, the only molecular marker existent until recently. These studies identified the presence of host-adapted *E. bieneusi* genotypes in several animals, and *E. bieneusi* genotypes with no host specificity, which are considered zoonotic. These zoonotic genotypes are responsible for most human infections. Some studies suggest that transmission of microsporidiosis due to some *E. bieneusi* genotypes could occur through person-to-person contact. This mode of transmission could be facilitated by chronic carriage of *E. bieneusi*, as described in some studies. Besides, several microsporidian species that infect humans have been identified in animals, especially mammals, raising public health concerns about zoonotic and waterborne transmission of microsporidia. In addition, some studies indicate that even some *E. bieneusi* genotypes, which are apparently unique in some animals, have zoonotic potential. Other studies indicate that the distribution of genotypes of *E. bieneusi* can vary by geographical locations and virulence.

Despite of the great genetic variation of *E. bieneusi* observed worldwide with the analyses of the ITS region of the rRNA gene, studies with additional independent markers for *E. bieneusi* are highly desirable in order to clarify the genetic structure of the parasite’s populations. The discrimination among strains of *E. bieneusi* is very important, not only for the clarification of the reservoirs and of the transmission modes of this pathogen but also to help to explain its variations in pathogenicity that cannot be answered with the study of a single locus.

### References

[1] K. Nageli, “Über die neue Krankheit die Seidenraupe unde verwandt Organismen,” *Botanische Zeitung*, vol. 15, pp. 760–761, 1857.

[2] I. Desportes, Y. Le Charpentier, A. Galian et al., “Occurrence of a new microsporidan: *Enterocytozoon bieneusi* n.g., n. sp., in the enterocytes of a human patient with AIDS,” *Journal of Protozoology*, vol. 32, no. 2, pp. 250–254, 1985.

[3] R. T. Bryan and D. A. Schwartz, "Epidemiology of microsporidiosis," in *The Microsporida and Microsporidiosis*, pp. 502–516, American Society For Microbiology, Washington, DC, USA, 1999.

[4] J. C. Gainzarin, A. Canut, M. Lozano et al., “Detection of *Enterocytozoon bieneusi* in two human immunodeficiency virus-negative patients with chronic diarrhea by polymerase chain reaction in duodenal biopsy specimens and review,” *Clinical Infectious Diseases*, vol. 27, no. 2, pp. 394–398, 1998.

[5] S. Leelayoova, I. Subrungruang, R. Rangsin et al., “Transmission of *Enterocytozoon bieneusi* genotype A in a Thai orphanage,” *American Journal of Tropical Medicine and Hygiene*, vol. 73, no. 1, pp. 104–107, 2005.

[6] R. Lopéz-Vélez, M. C. Turrientes, C. Garrón et al., "Microsporidiosis in travelers with diarrhea from the tropics," *Journal of Travel Medicine*, vol. 6, no. 4, pp. 223–227, 1999.
[7] B. Lores, I. López-Miragaya, C. Arias, S. Fenoy, J. Torres, and C. del Aguila, “Intestinal microsporidiosis due to Enterocytozoon bieneusi in elderly human immunodeficiency virus-negative patients from Vigo, Spain,” Clinical Infectious Diseases, vol. 34, no. 7, pp. 918–921, 2002.

[8] A. Müller, R. Bialek, A. Kämper, G. Fätkenheuer, B. Salzberger, and C. Franzen, “Detection of microsporidia in travelers with diarrhea,” Journal of Clinical Microbiology, vol. 39, no. 4, pp. 1630–1632, 2001.

[9] M. Munghin, I. Subrungruang, T. Naagl, P. Aimpun, W. Areekul, and S. Leelayoova, “Spore shedding pattern of Enterocytozoon bieneusi in asymptomatic children,” Journal of Medical Microbiology, vol. 54, no. 5, pp. 473–476, 2005.

[10] I. Sobottka, H. Albrecht, J. Schottelius et al., “Self-limited traveller’s diarrhea due to a dual infection with Enterocytozoon bieneusi and Cryptosporidium parvum in an immunocompetent HIV-negative child,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 14, no. 10, pp. 919–920, 1995.

[11] C. A. Wanke, “Enterocytozoon bieneusi infection and diarrheal disease in patients who were not infected with human immunodeficiency virus: case report and review,” Clinical Infectious Diseases, vol. 23, no. 4, pp. 816–818, 1996.

[12] E. Wichro, D. Hoelz, R. Krause, G. Bertha, F. Reinthaler, and C. Wenisch, “Microsporidiosis in travel-associated chronic diarrhea in immune-competent patients,” American Journal of Tropical Medicine and Hygiene, vol. 73, no. 2, pp. 285–287, 2005.

[13] F. Botterel, C. Minozzi, D. Vittecoq, and P. Bourée, “Pulmonary localization of Enterocytozoon bieneusi in an AIDS patient: case report and review,” Journal of Clinical Microbiology, vol. 40, no. 12, pp. 4800–4801, 2002.

[14] D. P. Kotler and J. M. Orenstein, “Clinical syndromes associated with microsporidiosis,” Advances in Parasitology, vol. 40, pp. 321–349, 1998.

[15] M. Sodqi, P. Brazille, G. Gonzalez-Canali, M. Cornet, C. Piketty, and L. Weiss, “Unusual pulmonary Enterocytozoon bieneusi microsporidiosis in an AIDS patient: case report and review,” Scandinavian Journal of Infectious Diseases, vol. 36, no. 3, pp. 230–231, 2004.

[16] J. M. Orenstein, J. Chiang, W. Steinberg, P. Smith, H. Albrecht, and D. P. Kotler, “Intestinal microsporidiosis as a cause of diarrhea in human immunodeficiency virus-infected patients: a report of 20 cases,” Human Pathology, vol. 21, no. 5, pp. 475–481, 1990.

[17] C. M. Coyle, M. Wittner, D. P. Kotler et al., “Prevalence of microsporidiosis due to Enterocytozoon bieneusi and Encephalitozoon (Septata) intestinalis among patients with AIDS-related diarrhea: determination by polymerase chain reaction to the microsporidian small-subunit RNA gene,” Clinical Infectious Diseases, vol. 23, no. 5, pp. 1002–1006, 1996.

[18] J. K. Tumwine, A. Kekitiinwa, N. Nabukenya, D. E. Akiyoshi, M. A. Buckholt, and S. Tziori, “Enterocytozoon bieneusi among children with diarrhea attending Mulago hospital in Uganda,” American Journal of Tropical Medicine and Hygiene, vol. 67, no. 3, pp. 299–303, 2002.

[19] W. Pagornrat, S. Leelayoova, R. Rangsir, P. Tan-Ariya, T. Naaglor, and M. Munghin, “Carriage rate of Enterocytozoon bieneusi in an orphanage in Bangkok, Thailand,” Journal of Clinical Microbiology, vol. 47, no. 11, pp. 3739–3741, 2009.

[20] B. Sak, D. Brady, M. Pelikánová et al., “Unapparent microsporidial infection among immunocompetent humans in the Czech Republic,” Journal of Clinical Microbiology, vol. 49, no. 3, pp. 1064–1070, 2011.

[21] P. Deplazes, A. Mathis, C. Müller, and R. Weber, “Molecular epidemiology of Encephalitozoon cuniculi and first detection of Enterocytozoon bieneusi in faecal samples of pigs,” Journal of Eukaryotic Microbiology, vol. 43, no. 3, Article ID 93S, 1996.

[22] K. G. Mansfield, A. Carville, D. Shvetz, J. Mackey, S. Tziori, and A. A. Lackner, “Identification of an Enterocytozoon bieneusi-like microsporidian parasite in simian-immunodeficiency-virus-inoculated macaques with hepatobiliary disease,” American Journal of Pathology, vol. 150, no. 4, pp. 1395–1405, 1997.

[23] C. del Aguila, F. Izquierdo, R. Navajas et al., “Enterocytozoon bieneusi in animals: rabbits and dogs as new hosts,” Journal of Eukaryotic Microbiology, vol. 46, no. 5, pp. 85–95, 1999.

[24] I. M. Sulaiman, R. Fayer, A. A. Lal, J. M. Trout, F. W. Schaefer III, and L. Xiao, “Molecular characterization of microsporidia indicates that wild mammals harbor host-adapted Enterocytozoon spp. as well as human-pathogenic Enterocytozoon bieneusi,” Applied and Environmental Microbiology, vol. 69, no. 8, pp. 4495–4501, 2003.

[25] I. M. Sulaiman, R. Fayer, C. Yang, M. Santin, O. Matos, and L. Xiao, “Molecular characterization of Enterocytozoon bieneusi in cattle indicates that only some isolates have zoonotic potential,” Parasitology Research, vol. 92, no. 4, pp. 328–334, 2004.

[26] M. L. Lobo, J. Xiao, V. Cama, T. Stevens, F. Antunes, and O. Matos, “Genotypes of Enterocytozoon bieneusi in mammals in Portugal,” Journal of Eukaryotic Microbiology, vol. 53, no. 1, pp. 561–564, 2006.

[27] N. Abe, I. Kimata, and M. Iseki, “Molecular evidence of Enterocytozoon bieneusi in Japan,” Journal of Veterinary Medical Science, vol. 71, no. 2, pp. 217–219, 2009.

[28] J. Reetz, K. Nöckler, S. Beckinger, M. M. Vargas, W. Weiske, and A. Broglia, “Identification of Encephalitozoon cuniculi genotype III and two novel genotypes of Enterocytozoon bieneusi in swine,” Parasitology International, vol. 58, no. 3, pp. 285–292, 2009.

[29] M. Santin, J. A. Cortés Vecino, and R. Fayer, “A zoonotic genotype of Enterocytozoon bieneusi in horses,” Journal of Parasitology, vol. 96, no. 1, pp. 157–161, 2010.

[30] X. Zhang, Z. Wang, Y. Su et al., “Identification and genotyping of Enterocytozoon bieneusi in China,” Journal of Clinical Microbiology, vol. 49, no. 5, pp. 2006–2008, 2011.

[31] B. Sak, M. Kváč, K. Petričklová et al., “Diversity of microsporidia (Fungi: Microsporidia) among captive great apes in European zoos and African sanctuaries: evidence for zoonotic transmission?” Folia Parasitologica, vol. 58, no. 2, pp. 81–86, 2011.

[32] W. Li, N. M. Kiulia, J. M. Mwenda et al., “Cyclospora sp., Cryptosporidium hominis, and human-pathogenic Enterocytozoon bieneusi in captive baboons in Kenya,” Journal of Clinical Microbiology, vol. 49, pp. 4326–4329, 2011.

[33] L. Cotte, M. Rabodonirina, F. Chappuis et al., “Waterborne outbreak of intestinal microsporidiosis in persons with and without human immunodeficiency virus infection,” Journal of Infectious Diseases, vol. 180, no. 6, pp. 2003–2008, 1999.

[34] C. Franzen and A. Müller, “Cryptosporidia and microsporidia—waterborne diseases in the immunocompromised host,” Diagnostic Microbiology and Infectious Disease, vol. 34, no. 3, pp. 245–262, 1999.

[35] H. W. A. Cheng, F. E. Lucy, T. K. Graczyk, M. A. Broaders, and S. E. Mastitsky, “Municipal wastewater treatment plants...
as removal systems and environmental sources of human-virulent microsporidian spores,” *Parasitology Research*, vol. 49, no. 12, pp. 4326–4329, 2011.

[36] D. M. Asmuth, P. C. DeGirolami, M. Federman et al., “Clinical features of microsporidiosis in patients with AIDS,” *Clinical Infectious Diseases*, vol. 18, no. 5, pp. 819–825, 1994.

[37] L. Cotte, M. Rabodonirina, M. A. Piens, M. Perreard, M. Mojon, and C. Trepo, “Prevalence of intestinal protozoans in French patients infected with HIV,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 6, no. 9, pp. 1024–1029, 1993.

[38] F. M. B. Ferreira, L. Bezzera, M. B. G. Santos, R. M. A. Bernardes, I. Avelino, and M. L. Sampaio Silva, “Intestinal microsporidiosis: a current infection in HIV-seropositive patients in Portugal,” *Microbes and Infection*, vol. 3, no. 12, pp. 1015–1019, 2001.

[39] A. S. Field, M. C. Hing, S. T. Milliken, and D. J. Marriott, “Microsporidia in the small intestine of HIV-infected patients. A new diagnostic technique and a new species,” *Medical Journal of Australia*, vol. 158, no. 6, pp. 390–394, 1993.

[40] T. Kyaw, A. Curry, V. Edwards-Jones, J. Craske, and B. K. Mandal, “The prevalence of *Enterocytozoon bieneusi* in acquired immunodeficiency syndrome (AIDS) patients from the north west of England: 1992–1995,” *British Journal of Biomedical Science*, vol. 54, no. 3, pp. 186–191, 1997.

[41] J. M. Molina, C. Sarfati, B. Beauvais et al., “Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biologic features,” *Journal of Infectious Diseases*, vol. 167, no. 1, pp. 217–221, 1993.

[42] W. Schmidt, T. Schneider, W. Heise et al., “Mucosal abnormalities in microsporidiosis,” *AIDS*, vol. 11, no. 13, pp. 1589–1594, 1997.

[43] I. Sobottka, D. A. Schwartz, J. Schottelius et al., “Prevalence and clinical significance of intestinal microsporidiosis in human immunodeficiency virus-infected patients with and without diarrhea in Germany: a prospective coprodiagnostic study,” *Clinical Infectious Diseases*, vol. 26, no. 2, pp. 475–480, 1998.

[44] M. C. Voglino, G. Donelli, P. Rossi et al., “Intestinal microsporidiosis in Italian individuals with AIDS,” *Italian Journal of Gastroenterology*, vol. 28, no. 7, pp. 381–386, 1996.

[45] M. L. Lobo, L. Xiao, F. Antunes, and O. Matos, “Microsporidia as emerging pathogens and the implication for public health: a 10-year study on HIV-positive and -negative patients,” *International Journal for Parasitology*, vol. 42, pp. 197–205, 2012.

[46] N. Abreu-Acosta, J. Lorenzo-Morales, Y. Leal-Guio et al., “*Enterocytozoon bieneusi* (microsporidia) in clinical samples from immunocompetent individuals in Tenerife, Canary Islands, Spain,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 99, no. 11, pp. 848–855, 2005.

[47] O. Alfa Cisse, A. Ouattara, M. Thellier et al., “Evaluation of an immunofluorescent-antibody test using monoclonal antibodies directed against *Enteroctozoon bieneusi* and *Encephalitozoon intestinalis* for diagnosis of intestinal microsporidiosis in bamako (Mali),” *Journal of Clinical Microbiology*, vol. 40, no. 5, pp. 1715–1718, 2002.

[48] C. Bern, V. Kawai, D. Vargas et al., “The epidemiology of intestinal microsporidiosis in patients with HIV/AIDS in Lima, Peru,” *Journal of Infectious Diseases*, vol. 191, no. 10, pp. 1658–1664, 2005.

[49] S. Bretagne, F. Foulet, W. Alkassoun, J. Fleury-Feith, and M. Develoux, “Prevalence of *Enterocytozoon bieneusi* spores in the stool of AIDS patients and African children not infected by HIV,” *Bulletin de la Societe de Pathologie Exotique*, vol. 86, no. 5, pp. 351–357, 1993.

[50] T. Gumbo, S. Sarbah, I. T. Gangaizdo et al., “Intestinal parasites in patients with diarrhea and human immunodeficiency virus infection in Zimbabwe,” *AIDS*, vol. 13, no. 7, pp. 819–821, 1999.

[51] I. Maiga, O. Doumbo, M. Dembele et al., “Human intestinal microsporidiosis in Bamako (Mali): the presence of *Enteroctozoon bieneusi* in HIV seropositive patients,” *Sante*, vol. 7, no. 4, pp. 257–262, 1997.

[52] K. Mohandas, R. Sehgal, A. Sud, and N. Malla, “Prevalence of intestinal parasitic pathogens in HIV-seropositive individuals in Northern India,” *Japanese Journal of Infectious Diseases*, vol. 55, no. 3, pp. 83–84, 2002.

[53] S. W. Nkinn, T. Asonganyi, E. S. Didier, and E. S. Kaneshiro, “Microsporidian infection is prevalent in healthy people in Cameroon,” *Journal of Clinical Microbiology*, vol. 45, no. 9, pp. 2841–2846, 2007.

[54] A. Samie, C. L. Obi, S. Tzipori, L. M. Weiss, and R. L. Guerrant, “Microsporidiosis in South Africa: PCR detection in stool samples of HIV-positive and HIV-negative individuals and school children in Vhembe district, Limpopo Province,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 101, no. 6, pp. 547–554, 2007.

[55] C. Sarfati, A. Bourgeois, J. Menotti et al., “Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional study,” *American Journal of Tropical Medicine and Hygiene*, vol. 74, no. 1, pp. 162–164, 2006.

[56] I. M. Sulaiman, C. Bern, R. Gilman et al., “A Molecular Biologic Study of *Enterocytozoon bieneusi* in HIV-Infected Patients in Lima, Peru,” *Journal of Eukaryotic Microbiology*, vol. 50, pp. 591–596, 2003.

[57] T. Van Gool, E. Luderhoff, K. J. Nathoo, C. F. Kiire, J. Dankert, and P. R. Mason, “High prevalence of *Enterocytozoon bieneusi* infections among HIV-positive individuals with persistent diarrhoea in Harare, Zimbabwe,” *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 89, no. 5, pp. 478–480, 1995.

[58] D. Wanachwanawin, “Intestinal microsporidiosis in HIV infected patients with chronic diarrhea in Thailand,” *South-Asian Journal of Tropical Medicine and Public Health*, vol. 29, no. 4, pp. 767–771, 1998.

[59] D. Waywa, S. Kongkirojngarj, S. Chaidatch et al., “Protozoan enteric infection in aids related diarrhea in Thailand,” *South East Asian Journal of Tropical Medicine and Public Health*, vol. 32, no. 2, pp. 151–155, 2001.

[60] R. Wumba, B. Longo-Mbenza, M. Mandina et al., “Intestinal parasites infections in hospitalized aids patients in kinshasa, democratic Republic of Congo,” *Parasite*, vol. 17, no. 4, pp. 321–328, 2010.

[61] T. Gumbo, I. T. Gangaizdo, S. Sarbah, A. Carville, S. Tzipori, and P. M. Wiest, “*Enterocytozoon bieneusi* infection in patients without evidence of immunosuppression: two cases from Zimbabwe found to have positive stools by PCR,” *Annals of Tropical Medicine and Parasitology*, vol. 94, no. 7, pp. 699–702, 2000.

[62] S. Anane, E. Kaouch, S. Belhadj et al., “Identification of *Enterocytozoon bieneusi* by PCR in stools of Tunisian immunocompromised patients,” *Pathologie Biologique*, vol. 59, no. 4, pp. 234–239, 2011.
[63] S. M. Valperga, S. A. de Joga Prat, G. J. O. de Valperga et al., “Microsporidian spores in the stool specimens of toddler, with or without diarrhea, from Tucuman, Argentina,” Revista Argentina de Microbiología, vol. 31, no. 3, pp. 157–164, 1999.

[64] J. K. Tumwine, A. Kekitiinwa, S. Bakeera-Kitaka et al., “Cryptosporidiosis and microsporidiosis in Ugandan children with persistent diarrhea and with and without concurrent infection with the human immunodeficiency virus,” American Journal of Tropical Medicine and Hygiene, vol. 73, no. 5, pp. 921–925, 2005.

[65] D. Wanachiwanawin, K. Chokephaibulkit, P. Lertlaituan, J. Ongrotchanakun, P. Chinabut, and K. Thakerngpol, “Intestinal microsporidiosis in HIV-infected children with diarrhea,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 33, no. 2, pp. 241–245, 2002.

[66] C. del Aguila, R. Navajas, D. Gurbindo et al., “Microsporidiosis in HIV-positive children in Madrid (Spain),” Journal of Eukaryotic Microbiology, vol. 44, no. 6, p. 84, 1997.

[67] A. B. Ayinnmode, O. T. Ojurimi, and L. Xiao, “Molecular Identification of Enterocytozoon bieneusi Isolates from Nigerian Children,” Journal of Parasitology Research, vol. 2011, Article ID 129542, 2 pages, 2011.

[68] O. T. Ojurimi, F. Izquierdo, S. Fenoy et al., “Identification and characterization of microsporidia from fecal samples of HIV-positive patients from Lagos, Nigeria,” PLoS ONE, vol. 7, no. 4, 2012.

[69] M. Munghim, R. Suvannasaeng, T. Naaglor, W. Areekul, and S. Leelayoova, “Asymptomatic intestinal microsporidiosis in Thai orphans and child-care workers,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 95, no. 3, pp. 304–306, 2001.

[70] C. N. Conteas, O. G. W. Berlin, M. J. Lariviere et al., “Examination of the prevalence and seasonal variation of intestinal microsporidiosis in the stools of persons with chronic diarrhea and human immunodeficiency virus infection,” American Journal of Tropical Medicine and Hygiene, vol. 58, no. 5, pp. 559–561, 1998.

[71] R. Weber, B. Ledergerber, R. Zbinden et al., “Enteric infections and diarrhea in human virus-injected persons: prospective community-based cohort study,” Archives of Internal Medicine, vol. 159, no. 13, pp. 1473–1480, 1999.

[72] T. P. R. Bachur, J. M. Vale, I. C. B. Cˆoelho, T. R. B. S. de Queiroz, and C. de Souza Chaves, “Enteric parasitic infections in HIV/AIDS patients before and after the highly active antiretroviral therapy,” Brazilian Journal of Infectious Diseases, vol. 12, no. 2, pp. 115–122, 2008.

[73] C. R. Vossbrinck, J. V. Maddox, and S. Friedman, “Ribosomal RNA sequence suggests microsporidia are extremely ancient eukaryotes,” Nature, vol. 326, no. 6111, pp. 411–414, 1987.

[74] J. M. Orenstein, W. Zierdt, C. Zierdt, and D. P. Kotler, “Identification of spores of Enterocytozoon bieneusi in stool and duodenal fluid from AIDS patients,” The Lancet, vol. 336, no. 8723, pp. 1127–1128, 1990.

[75] V. A. Cama, J. Pearson, L. Cabrera et al., “Transmission of Enterocytozoon bieneusi between a child and guinea pigs,” Journal of Clinical Microbiology, vol. 45, no. 8, pp. 2708–2710, 2007.

[76] A. Espern, F. Morio, M. Miegeville et al., “Molecular study of microsporidiosis due to Enterocytozoon bieneusi and Encephalitozoon intestinalis among human immunodeficiency virus-infected patients from two geographical areas: Niamey, Niger, and Hanoi, Vietnam,” Journal of Clinical Microbiology, vol. 45, no. 9, pp. 2999–3002, 2007.

[77] J. P. Cegielski, Y. R. Ortega, S. McKee et al., “Cryptosporidium Enterocytozoon, and Cyclospora infections in pediatric and adult patients with diarrhea in Tanzania,” Clinical Infectious Diseases, vol. 28, no. 2, pp. 314–321, 1999.

[78] D. P. Kotler, A. Francisco, F. Clayton, J. V. Scholes, and J. M. Orenstein, “Small intestinal injury and parasitic diseases in AIDS,” Annals of Internal Medicine, vol. 113, no. 6, pp. 444–449, 1990.

[79] J. K. Greenson, P. C. Belitsos, J. H. Yardley, and J. G. Bartlett, “AIDS enteropathy: occult enteric infections and duodenal mucosal alterations in chronic diarrhea,” Annals of Internal Medicine, vol. 114, no. 5, pp. 366–372, 1991.

[80] S. Leelayoova, N. Vithayasai, W. Watanaaveeradej et al., “Intestinal microsporidiosis in HIV-infected children with acute and chronic diarrhea,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 32, no. 1, pp. 33–37, 2001.

[81] S. M. Mor, J. K. Tumwine, E. N. Naumova, G. Ndeei, and S. Tzipori, “Microsporidiosis and malnutrition in children with persistent diarrhea, Uganda,” Emerging Infectious Diseases, vol. 15, no. 1, pp. 49–52, 2009.

[82] T. Endeshaw, A. Kebede, J. J. Verweij et al., “Intestinal microsporidiosis in diarrheal patients infected with human immunodeficiency virus-1 in Addis Ababa, Ethiopia,” Japanese Journal of Infectious Diseases, vol. 59, no. 5, pp. 306–310, 2006.

[83] L. Rabeneck, F. Gyorkey, R. M. Genta, P. Gyorkey, L. W. Foote, and J. M. H. Risser, “The role of Microsporidia in the pathogenesis of HIV-related chronic diarrhea,” Annals of Internal Medicine, vol. 119, no. 9, pp. 895–899, 1993.

[84] J. E. Clarridge, S. Karkhanis, L. Rabeneck, B. Marino, and L. W. Foote, “Quantitative light microscopic detection of Enterocytozoon bieneusi in stool specimens: a longitudinal study of human immunodeficiency virus-infected microsporidiosis patients,” Journal of Clinical Microbiology, vol. 34, no. 3, pp. 520–523, 1996.

[85] L. Chacin-Bonilla, A. P. Panunzio, F. M. Monsalve-Castillo, I. E. Parra-Cepeda, and R. Martinez, “Microsporidiosis in Venezuela: prevalence of intestinal microsporidiosis and its contribution to diarrhea in a group of human immunodeficiency virus-infected patients from Zulia State,” American Journal of Tropical Medicine and Hygiene, vol. 74, no. 3, pp. 482–486, 2006.

[86] K. Dascomb, T. Frazer, R. A. Clark, P. Kissinger, and E. Didier, “Microsporidiosis and HIV,” Journal of Acquired Immune Deficiency Syndromes, vol. 24, no. 3, pp. 290–292, 2000.

[87] O. I. Sokolova, A. V. Demyanov, L. C. Bowers et al., “Emerging microsporidian infections in Russian HIV-infected patients,” Journal of Clinical Microbiology, vol. 49, no. 6, pp. 2102–2108, 2011.

[88] J. H. Botero, M. N. Montoya, A. L. Vanegas et al., “Frequency of intestinal microsporidian infections in HIV-positive patients, as diagnosis by quick hot Gram chromotrope staining and PCR,” Biomedica, vol. 24, no. 4, pp. 375–384, 2004.

[89] P. Brasil, D. B. de Lima, D. D. de Paiva et al., “Clinical and diagnostic aspects of intestinal microsporidiosis in HIV-infected patients with chronic diarrhea in Rio de Janeiro, Brazil,” Revista do Instituto de Medicina Tropical de Sao Paulo, vol. 42, no. 6, pp. 299–304, 2000.

[90] A. A. Escobedo and F. A. N ´u˜nez, “Prevalence of intestinal parasites in Cuban acquired immunodeficiency syndrome (AIDS) patients,” Acta Tropic, vol. 72, no. 1, pp. 125–130, 1999.
[91] E. Bernard, M. Carles, C. Pradier et al., “Chronic diarrhoea in HIV+ patients: role of Enterocytozoon bieneusi,” *Presse Medica*, vol. 24, no. 14, pp. 671–674, 1995.

[92] O. Liguory, C. Sarfati, F. Derouin, and J. M. Molina, “Evidence of different Enterocytozoon bieneusi genotypes in patients with and without human immunodeficiency virus infection,” *Journal of Clinical Microbiology*, vol. 39, no. 7, pp. 2672–2674, 2001.

[93] C. Franzen, A. Müller, P. Hegener et al., “Polymerase chain reaction for microsporidian DNA in gastrointestinal biopsy specimens of HIV-infected patients,” *AIDS*, vol. 10, no. 8, pp. F23–F27, 1996.

[94] H. Rinder, S. Katzwinkel-Wladarsch, and T. Löscher, “Evidence for the existence of genetically distinct strains of Enterocytozoon bieneusi,” *Parasitology Research*, vol. 83, no. 7, pp. 670–672, 1997.

[95] B. Dengjel, M. Zahler, W. Hermanns et al., “Zoonotic potential of Enterocytozoon bieneusi,” *Journal of Clinical Microbiology*, vol. 39, no. 12, pp. 4495–4499, 2001.

[96] T. Van Gool, F. Snijders, P. Reiss et al., “Diagnosis of intestinal and disseminated microsporidial infections in patients with HIV by a new rapid fluorescence technique,” *Journal of Clinical Pathology*, vol. 46, no. 8, pp. 694–699, 1993.

[97] S. D. Polley, S. Boadi, J. Watson, A. Curry, and P. L. Chiodini, “Detection and species identification of microsporidial infections using SYBR Green real-time PCR,” *Journal of Medical Microbiology*, vol. 60, no. 4, pp. 459–466, 2011.

[98] Z. Kucerova, O. I. Sokolova, A. V. Demyanov et al., “Microsporidiosis and cryptosporidiosis in HIV/AIDS patients in St. Petersburg, Russia: serological identification of microsporidia and Cryptosporidium parvum in sera samples from HIV/AIDS patients,” *AIDS Research and Human Retroviruses*, vol. 27, no. 1, pp. 13–15, 2011.

[99] J. Breton, E. Bart-Delabesse, S. Biligui et al., “New highly divergent rRNA sequence among biodiverse genotypes of Enterocytozoon bieneusi strains isolated from humans in Gabon and Cameroon,” *Journal of Clinical Microbiology*, vol. 45, no. 8, pp. 2580–2589, 2007.

[100] F. Drobniewski, P. Kelly, A. Carew et al., “Human microsporidiosis in African AIDS patients with chronic diarrhoea,” *Journal of Infectious Diseases*, vol. 171, no. 2, pp. 515–516, 1995.

[101] H. Rinder, S. Katzwinkel-Wladarsch, A. Thomschke, and T. Löscher, “Strain differentiation in microsporidia,” *Tokai Journal of Experimental and Clinical Medicine*, vol. 23, no. 6, pp. 433–438, 1998.

[102] W. Saksirisampant, P. Prownebon, P. Saksirisampant, M. Munthin, S. Siripatanapong, and S. Leelayoova, “Intestinal parasitic infections: prevalences in HIV/AIDS patients in a Thai AIDS-care centre,” *Annals of Tropical Medicine and Parasitology*, vol. 103, no. 7, pp. 573–581, 2009.

[103] N. J. Ryan, G. Sutherland, K. Coughlan et al., “A new trichrome-blue stain for detection of microsporidial species in urine, stool, and nasopharyngeal specimens,” *Journal of Clinical Microbiology*, vol. 31, no. 12, pp. 3264–3269, 1993.

[104] S. Katzwinkel-Wladarsch, M. Lieb, W. Heise, T. Löscher, and H. Rinder, “Direct amplification and species determination of microsporidian DNA from stool specimens,” *Tropical Medicine and International Health*, vol. 1, no. 3, pp. 373–378, 1996.

[105] S. Coupe, K. Delabre, R. Pouillot, S. Houdart, M. Santillana-Hayat, and F. Derouin, “Detection of Cryptosporidium, Giardia and Enterocytozoon bieneusi in surface water, including recreational areas: a one-year prospective study,” *FEMS Immunology and Medical Microbiology*, vol. 47, no. 3, pp. 351–359, 2006.

[106] J. M. Sparfel, C. Sarfati, O. Liguory et al., “Detection of microsporidia and identification of Enterocytozoon bieneusi in surface water by filtration followed by specific PCR,” *Journal of Eukaryotic Microbiology*, vol. 44, supplement S6, p. 78S, 1997.

[107] J. A. Thurston-Enriquez, P. Watt, S. E. Dowd, R. Enriquez, I. L. Pepper, and C. P. Gerba, “Detection of protozoan parasites and microsporidia in irrigation waters used for crop production,” *Journal of Food Protection*, vol. 65, no. 2, pp. 378–382, 2002.

[108] A. L. Galván, A. M. M. Sánchez, M. A. P. Valentín et al., “First cases of microsporidiosis in transplant recipients in Spain and review of the literature,” *Journal of Clinical Microbiology*, vol. 49, no. 4, pp. 1301–1306, 2011.

[109] O. Liguory, F. David, C. Sarfati, F. Derouin, and J. M. Molina, “Determination of types of Enterocytozoon bieneusi strains isolated from patients with intestinal microsporidiosis,” *Journal of Clinical Microbiology*, vol. 36, no. 7, pp. 1882–1885, 1998.

[110] H. Rinder, B. Dengjel, R. Gothe, and T. Löscher, “Microsporidiosis of man: where is the reservoir?” *Mitt Osterr Ges Truppenparasitol*, vol. 22, pp. 1–6, 2000.

[111] F. Sadler, N. Peake, R. Borrow, P. L. Rowl, E. G. L. Wilkins, and A. Curry, “Genotyping of Enterocytozoon bieneusi in AIDS patients from the north west of England,” *Journal of Infection*, vol. 44, no. 1, pp. 39–42, 2002.

[112] R. J. Ten Hove, L. Van Lieshout, M. B. J. Beadsworth et al., “Characterization of genotypes of Enterocytozoon bieneusi in immunosuppressed and immunocompetent patient groups,” *Journal of Eukaryotic Microbiology*, vol. 56, no. 4, pp. 388–393, 2009.

[113] S. Leelayoova, I. Subrungruang, Y. Suputtamongkol, J. Worapong, P. C. Petmir, and M. Munthin, “Identification of genotypes of Enterocytozoon bieneusi from stool samples from human immunodeficiency virus-infected patients in Thailand,” *Journal of Clinical Microbiology*, vol. 44, no. 8, pp. 3001–3004, 2006.

[114] S. Leelayoova, P. Piayaraj, I. Subrungruang et al., “Genotypic characterization of Enterocytozoon bieneusi in specimens from pigs and humans in a pig farm community in central Thailand,” *Journal of Clinical Microbiology*, vol. 47, no. 5, pp. 1572–1574, 2009.

[115] D. Stark, S. van Hal, J. Barratt, J. Ellis, D. Marriott, and J. Harkness, “Limited genetic diversity among genotypes of Enterocytozoon bieneusi strains isolated from HIV-infected patients from Sydney, Australia,” *Journal of Medical Microbiology*, vol. 56, no. 3, pp. 355–357, 2009.

[116] N. Abe and I. Kimata, “Molecular survey of Enterocytozoon bieneusi in a Japanese porcine population,” *Vector-Borne and Zoonotic Diseases*, vol. 10, no. 4, pp. 425–427, 2010.

[117] D. Kasichová, B. Sak, M. Kvač, and O. Ditrich, “Sources of potentially infectious human microsporidia: molecular characterisation of microsporidia isolates from exotic birds in the Czech Republic, prevalence study and importance of birds in epidemiology of the human microsporidial infections,” *Veterinary Parasitology*, vol. 165, no. 1–2, pp. 125–130, 2009.

[118] L. V. Chalifoux, A. Carville, D. Pauley, B. Thompson, A. A. Lackner, and K. G. Mansfield, “Enterocytozoon bieneusi as a cause of proliferative serositis in simian immunodeficiency virus-infected immunodeficient macaques (Macaca sylvanus).” *Annals of Tropical Medicine and Parasitology*, vol. 101, no. 7, pp. 627–633, 2007.
mulatta),” *Archives of Pathology and Laboratory Medicine*, vol. 124, no. 10, pp. 1480–1484, 2000.

[119] M. A. Buckholt, J. H. Lee, and S. Tzipori, “Prevalence of *Enterocytozoon bieneusi* in swine: an 18-month survey at a slaughterhouse in Massachusetts,” *Applied and Environmental Microbiology*, vol. 68, no. 5, pp. 2595–2599, 2002.

[120] D. K. Jeong, G. Y. Won, B. K. Park et al., “Occurrence and genotypic characteristics of *Enterocytozoon bieneusi* in pigs with diarrhea,” *Parasitology Research*, vol. 102, no. 1, pp. 123–128, 2007.

[121] A. C. Breitenmoser, A. Mathis, E. Bürgi, R. Weber, and P. Deplazes, “High prevalence of *Enterocytozoon bieneusi* in swine with four genotypes that differ from those identified in humans,” *Parasitology*, vol. 118, no. 5, pp. 447–453, 1999.

[122] M. Santín, J. M. Trout, J. A. C. Vecino, J. P. Dubey, and R. Fayer, “Cryptosporidium, Giardia and *Enterocytozoon bieneusi* in cats from Bogota (Colombia) and genotyping of isolates,” *Veterinary Parasitology*, vol. 141, no. 3–4, pp. 334–339, 2006.

[123] M. Santín, J. A. Cortés Vecino, and R. Fayer, “*Enterocytozoon bieneusi* genotypes in dogs in Bogota, Colombia,” *American Journal of Tropical Medicine and Hygiene*, vol. 79, no. 2, pp. 215–217, 2008.

[124] J. H. Lee, “Molecular detection of *Enterocytozoon bieneusi* and identification of a potentially human-pathogenic genotype in milk,” *Applied and Environmental Microbiology*, vol. 74, no. 5, pp. 1664–1666, 2008.

[125] M. L. Lobo, L. Xiao, V. Cama, N. Magalhães, F. Antunes, and O. Matos, “Identification of potentially human-pathogenic *Enterocytozoon bieneusi* genotypes in various birds,” *Applied and Environmental Microbiology*, vol. 72, no. 11, pp. 7380–7382, 2006.

[126] M. Santín, J. M. Trout, and R. Fayer, “*Enterocytozoon bieneusi* genotypes in dairy cattle in the eastern United States,” *Parasitology Research*, vol. 97, no. 6, pp. 535–538, 2005.

[127] B. Sak, M. Kvač, D. Hanzliková, and V. Cama, “First report of *Enterocytozoon bieneusi* infection on a pig farm in the Czech Republic,” *Veterinary Parasitology*, vol. 153, no. 3–4, pp. 220–224, 2008.

[128] H. Rinder, A. Thomschke, B. Dengiel, R. Gothe, T. Löschner, and M. Zahler, “Close genotypic relationship between *Enterocytozoon bieneusi* from humans and pigs and first detection in cattle,” *Journal of Parasitology*, vol. 86, no. 1, pp. 185–188, 2000.

[129] J. H. Lee, “Prevalence and molecular characteristics of *Enterocytozoon bieneusi* in cattle in Korea,” *Parasitology Research*, vol. 101, no. 2, pp. 391–396, 2007.

[130] R. Fayer, M. Santín, and J. M. Trout, “*Enterocytozoon bieneusi* in mature dairy cattle on farms in the eastern United States,” *Parasitology Research*, vol. 102, no. 1, pp. 15–20, 2007.

[131] J. Reetz, H. Rinder, A. Thomschke, H. Manke, M. Schwebs, and A. Bruderek, “First detection of the microsporidium *Enterocytozoon bieneusi* in non-mammalian hosts (chickens),” *International Journal for Parasitology*, vol. 32, no. 7, pp. 785–787, 2002.

[132] F. Izquierdo, J. A. Castro Hermida, S. Fenoy, M. Mezo, M. González-Warleta, and C. D. Aguila, “Detection of microsporidia in drinking water, wastewater and recreational rivers,” *Water Research*, vol. 45, no. 16, pp. 4837–4843, 2011.

[133] S. Tzipori, A. Carville, G. Widmer, D. Kotler, K. Mansfield, and A. Lackner, “Transmission and establishment of a persistent infection of *Enterocytozoon bieneusi*, derived from a human with AIDS, in simian immunodeficiency virus-infected rhesus monkeys,” *Journal of Infectious Diseases*, vol. 175, no. 4, pp. 1016–1020, 1997.